<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>12</ref-type><contributors><translated-authors><author><style face="normal" font="default" size="100%">MTBEurope: Technology for Healthcare</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">FDA will be overstretched by need to monitor medical nanotechnology</style></title><secondary-title><style face="normal" font="default" size="100%">Medical Technology Business Europe</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style  face="normal" font="default" size="100%">October 13, 2006</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.mtbeurope.info/news/2006/610021.htm</style></url></web-urls></urls><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Article reporting on the report by former FDA Deputy Commissioner for Policy Michael R. Taylor, Regulating the Products of Nanotechnology: Does FDA have the Tools It Needs? released by The Project on Emerging Nanotechnologies. Article warns that with developments in medical nanotechnology are advancing at such a rapid rate, the US Food and Drug Administration is unlikely to be able to cope with the requirements to properly monitor them.</style></abstract><work-type><style face="normal" font="default" size="100%">Newsletter article</style></work-type></record></records></xml>